Trials / Not Yet Recruiting
Not Yet RecruitingNCT07468396
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
A Phase I, Single-arm, Open-label, Multi-center Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GLR2037 in Patients With Metastatic Prostate Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Gan & Lee Pharmaceuticals. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLR2037 | GLR2037 administered QD for 28 day cycles. |
Timeline
- Start date
- 2026-04-30
- Primary completion
- 2031-10-30
- Completion
- 2033-04-30
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07468396. Inclusion in this directory is not an endorsement.